Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Share-based Compensation (2018 - 2025)

Historic Share-based Compensation for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to $760000.0.

  • X4 Pharmaceuticals' Share-based Compensation fell 5824.18% to $760000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $4.2 million, marking a year-over-year decrease of 5022.28%. This contributed to the annual value of $8.2 million for FY2024, which is 556.0% down from last year.
  • Latest data reveals that X4 Pharmaceuticals reported Share-based Compensation of $760000.0 as of Q3 2025, which was down 5824.18% from $748000.0 recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Share-based Compensation peaked at $2.5 million during Q4 2023, and registered a low of $519000.0 during Q1 2025.
  • In the last 5 years, X4 Pharmaceuticals' Share-based Compensation had a median value of $1.6 million in 2021 and averaged $1.6 million.
  • In the last 5 years, X4 Pharmaceuticals' Share-based Compensation soared by 12935.86% in 2023 and then tumbled by 7015.53% in 2025.
  • X4 Pharmaceuticals' Share-based Compensation (Quarter) stood at $1.6 million in 2021, then tumbled by 31.2% to $1.1 million in 2022, then skyrocketed by 129.36% to $2.5 million in 2023, then decreased by 12.68% to $2.2 million in 2024, then crashed by 65.72% to $760000.0 in 2025.
  • Its Share-based Compensation stands at $760000.0 for Q3 2025, versus $748000.0 for Q2 2025 and $519000.0 for Q1 2025.